Intra-Cellular Therapies Inc. (ITCI) Shares Up 1.8%
Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shot up 1.8% on Friday . The company traded as high as $39.74 and last traded at $39.61, with a volume of 155,899 shares. The stock had previously closed at $38.90.
A number of research firms have weighed in on ITCI. Leerink Swann reissued an “outperform” rating and set a $95.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, March 21st. Cowen and Company reissued a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, June 29th. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Tuesday, May 17th. Piper Jaffray Cos. began coverage on shares of Intra-Cellular Therapies in a report on Wednesday, June 1st. They set an “overweight” rating and a $57.00 price objective on the stock. Finally, SunTrust Banks Inc. reissued a “top pick” rating and set a $60.00 price objective on shares of Intra-Cellular Therapies in a report on Tuesday, March 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $70.78.
The firm’s 50-day moving average price is $38.89 and its 200-day moving average price is $35.60. The stock’s market cap is $1.71 billion.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.14. Equities research analysts anticipate that Intra-Cellular Therapies Inc. will post ($3.14) earnings per share for the current year.
Other institutional investors recently added to or reduced their stakes in the company. Jennison Associates bought a new position in Intra-Cellular Therapies during the third quarter worth $16,096,000. California State Teachers Retirement System boosted its position in Intra-Cellular Therapies by 24.9% in the fourth quarter. California State Teachers Retirement System now owns 49,381 shares of the biopharmaceutical company’s stock worth $2,656,000 after buying an additional 9,852 shares in the last quarter. Sei Investments Co. bought a new position in Intra-Cellular Therapies during the fourth quarter worth $4,539,000. Rhumbline Advisers boosted its position in Intra-Cellular Therapies by 33.1% in the fourth quarter. Rhumbline Advisers now owns 25,503 shares of the biopharmaceutical company’s stock worth $1,372,000 after buying an additional 6,345 shares in the last quarter. Finally, Oxford Asset Management bought a new position in Intra-Cellular Therapies during the fourth quarter worth $1,988,000.
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.